von Willebrand factor (Recombinant) (Vonvendi)
von Willebrand factor (Recombinant) is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2015
Reference approved
Reference product
Vonvendi von Willebrand factor (Recombinant)
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Dec 08, 2015
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for von Willebrand factor (Recombinant), in chronological order.
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
13 yr 1 mo ago
Reference approval
Approval date of the reference von Willebrand factor (Recombinant) product.
10 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for von Willebrand factor (Recombinant) (Vonvendi)?
No 351(k) biosimilars or interchangeable biosimilars referencing von Willebrand factor (Recombinant) are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.